 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Policy Experts Say Myriad's Proprietary Variant Database Sets Bad Precedent for Personalized Medicine
November 02, 2012
Policy Experts Say Myriad's Proprietary Variant Database Sets Bad Precedent for Personalized Medicine
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing MDx Pipeline
August 10, 2011 / Pharmacogenomics Reporter - Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business
November 3, 2010 / Pharmacogenomics Reporter - In Wake of Myriad Decision, Some Debate Licensing Models for Gene Patents, While Some Question Value
April 28, 2010 / Pharmacogenomics Reporter - Myriad Plans to Sell Harder During Weak Economy; Reports Slowdown in Revenue Growth
August 26, 2009 / Pharmacogenomics Reporter - Myriad to Replace BRACAnalysis, Other Hereditary Cancer Tests with MyRisk Panel
May 9, 2013 / GenomeWeb Daily News